Dr. Narasimhan said the company is hoping to file for emergency use authorization within the next month.
On Jan. 10, Novartis released data showing the drug, ensovibep, reduced the risk of hospitalization, emergency room visits or death by 78 percent compared to a placebo group. The drug also reduced the viral load in patients’ bodies over eight days, which was the study’s main endpoint.
Based on positive results from the phase 2 trial, which involved 407 adults, Novartis said it is exercising an option to license ensovibep from Molecular Partners, a Swiss biopharmaceutical company.
A larger clinical trial to confirm this data is expected to wrap up by the second half of 2022, Dr. Narasimhan told Bloomberg Law.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
